Daily Endocrinology Research Analysis
Three impactful endocrinology-related studies span mechanistic immunometabolism, neuroendocrine adverse effect biology, and endocrine drug safety. Obesity-driven expansion of visceral adipose CD8+ T cells via IFNα/IFNAR signaling mechanistically worsens inflammatory arthritis, GLP-1 receptor agonists induce emesis through postsynaptic AMPA receptor signaling in the area postrema, and pasireotide in acromegaly increases glycemia and diabetes risk while raising HDL-C.
Summary
Three impactful endocrinology-related studies span mechanistic immunometabolism, neuroendocrine adverse effect biology, and endocrine drug safety. Obesity-driven expansion of visceral adipose CD8+ T cells via IFNα/IFNAR signaling mechanistically worsens inflammatory arthritis, GLP-1 receptor agonists induce emesis through postsynaptic AMPA receptor signaling in the area postrema, and pasireotide in acromegaly increases glycemia and diabetes risk while raising HDL-C.
Research Themes
- Immunometabolic crosstalk linking obesity to autoimmunity
- Neural mechanisms of GLP-1RA-induced emesis
- Metabolic safety of endocrine therapies (pasireotide in acromegaly)
Selected Articles
1. Adipose tissue harbors pathogenic T cells in obesity that exacerbate inflammatory arthritis.
In an antigen-induced arthritis model, obesity drives visceral adipose tissue (VAT) as a niche where CD8+ T cells expand under IFNα signaling and aggravate arthritis. VAT transplantation exacerbated disease, IFNα (but not IFNγ) expanded VAT CD8+ T cells, and T cell–specific Ifnar1 deletion attenuated arthritis in obese mice, establishing an adipose–immune axis linking obesity to autoimmunity.
Impact: This study mechanistically ties obesity to autoimmunity via IFNα-driven expansion of adipose CD8+ T cells, revealing a druggable IFNAR pathway. It reframes adipose tissue as an active immunological organ influencing systemic inflammatory disease.
Clinical Implications: Targeting IFNα/IFNAR signaling or adipose-resident CD8+ T cells may mitigate arthritis severity in obese patients; prioritizing weight reduction could reduce autoimmune disease burden via immunologic mechanisms.
Key Findings
- Obesity (HFD) promotes homing and expansion of arthritis-inducing CD8+ OT-I T cells within visceral adipose tissue (VAT).
- VAT transplantation from arthritic mice worsened arthritis in recipients; disease was ameliorated by CD8+ T cell depletion.
- IFNα (but not IFNγ) expanded VAT CD8+ T cells; global and T cell–specific Ifnar1 deletion reduced VAT CD8+ expansion and arthritis severity.
Methodological Strengths
- Use of trackable antigen-specific CD8+ T cells and VAT transplantation to demonstrate causality.
- Genetic dissection with global and T cell–specific Ifnar1 deletion plus cytokine administration and bulk RNA-seq.
Limitations
- Findings are preclinical and based on mouse antigen-induced arthritis models.
- Human VAT T cell phenotypes and translatability to diverse autoimmune diseases remain untested.
Future Directions: Profile adipose-resident T cells in obese patients with arthritis; test IFNAR pathway inhibitors or anti-IFNα strategies in obesity-associated autoimmunity; examine whether weight loss modulates VAT T cell programs and disease activity.
Obesity worsens inflammatory arthritis severity, even in non-load-bearing joints, but the mechanism is unknown. Here, we show that there is an immunological mechanism mediated by T cells in adipose tissue. Using an antigen-induced arthritis model with trackable, arthritis-inducing CD8+ OT-I T cells, we found that OT-I T cells home to visceral adipose tissue (VAT) and expand there in the obese high-fat diet (HFD) context. Transplant of VAT from arthritic mice increased arthritis severity in naïve recipient mice and was ameliorated by CD8 T cell depletion. Bulk RNA sequencing identified pro-inflammatory changes to OT-I T cells in VAT characterized by increased IFN α and γ signaling after HFD. Intraperitoneal injection of IFNα, but not IFNγ, expanded CD8 T cell numbers in VAT. HFD-induced expansion of VAT CD8 T cells was ameliorated with global Ifnar1 deletion, and importantly, genetic deletion of Ifnar1 in T cells decreased arthritis severity in obese mice. These results provide a mechanistic explanation of how obesity worsens autoimmunity.
2. Exendin-4 induced retching-like behavior mediated by postsynaptic effect via AMPA receptors in the area postrema of mice.
Exendin-4 triggers retching-like behavior via GLP-1 receptors in the area postrema, independent of vagal afferents, and through postsynaptic AMPA receptor signaling. Genetic deletion of GLP-1R in the area postrema abolished emesis-like behavior, highlighting a tractable neural target to mitigate GLP-1–related nausea/vomiting.
Impact: Identifying a postsynaptic AMPA receptor–dependent mechanism in the area postrema directly addresses a major tolerability barrier of GLP-1R agonists used in diabetes and obesity, opening avenues for adjunct antiemetic strategies.
Clinical Implications: Modulation of AMPA receptor signaling or selective targeting of area postrema GLP-1R circuits could reduce GLP-1RA-induced nausea/vomiting without compromising metabolic efficacy.
Key Findings
- Exendin-4 induces dose-dependent retching-like behavior replicated by direct administration into the area postrema.
- Vagal afferent denervation did not attenuate Exendin-4–induced retching, whereas area postrema–specific GLP-1R deletion abolished it.
- Mechanistically, Exendin-4 enhances neuronal activity via a postsynaptic AMPA receptor–dependent pathway in area postrema GLP-1R neurons.
Methodological Strengths
- Combined systemic and site-specific microinjection approaches with behavioral quantification.
- Genetic ablation of GLP-1R in the area postrema and vagal denervation to dissect circuit mechanisms.
Limitations
- Mouse retching-like behavior may not fully recapitulate human nausea/vomiting.
- Did not test pharmacologic AMPA receptor antagonists or off-target effects in vivo.
Future Directions: Evaluate whether AMPA receptor antagonists or circuit-level neuromodulation can mitigate GLP-1RA-induced nausea; map human area postrema GLP-1R circuits and translational biomarkers of emesis.
Although glucagon-like peptide-1 (GLP-1) analogs have been clinically approved for type 2 diabetes mellitus (T2DM) and obesity treatment for an extended period, their associated adverse effects of nausea and vomiting remain unsolved. To elucidate the neural mechanisms underlying GLP-1-induced emesis, we investigated how GLP-1 signaling in the area postrema (AP) modulates retching-like behavior in mice. Our experiments demonstrated that intraperitoneal administration of the GLP-1 receptor agonist Exendin-4 (Exn4) induced dose-dependent retching-like behavior, which was replicated by direct Exn4 administration into the AP. Notably, while vagal afferent denervation failed to attenuate Exn4-induced retching-like behavior, genetic ablation of GLP-1 receptor (GLP-1R) expression in the AP completely abolished this response, establishing AP GLP-1R as the critical mediator of GLP-1-associated emesis. Further mechanistic studies revealed that Exn4 enhances AP GLP-1R neuronal activity through a postsynaptic pathway dependent on AMPA receptor signaling. These findings provide a neural circuit basis for GLP-1-induced emesis and identify a potential therapeutic target for mitigating this clinically significant side effect.
3. Impact of pasireotide on lipid and glucose metabolism in patients with acromegaly: a systematic review and meta-analysis.
Across 19 studies (896 patients), pasireotide LAR increased fasting plasma glucose (MD 23.4 mg/dL), HbA1c, HDL-C, and diabetes frequency, with no effect on triglycerides, total cholesterol, or LDL-C. Findings held across monotherapy and combination therapy with pegvisomant and over ≥6 months of follow-up.
Impact: This meta-analysis consolidates metabolic safety signals of pasireotide in acromegaly, quantifying dysglycemia risk and clarifying lipid effects to guide risk-benefit discussions and monitoring protocols.
Clinical Implications: Clinicians should proactively monitor and manage hyperglycemia when prescribing pasireotide (baseline and on-treatment FPG/HbA1c), consider combination strategies (e.g., pegvisomant) judiciously, and counsel patients that HDL-C may increase without adverse LDL-C/TG effects.
Key Findings
- Pasireotide LAR increased fasting plasma glucose by 23.4 mg/dL (95% CI 18.8–28.1) and raised HbA1c.
- Diabetes frequency increased under pasireotide, while HDL-C increased and triglycerides, total cholesterol, and LDL-C were unchanged.
- Effects were observed in studies with ≥6 months’ follow-up and included monotherapy or combination with pegvisomant.
Methodological Strengths
- Systematic search across four databases with pre-registration (PROSPERO CRD42024544686).
- Inclusion of 19 studies (896 patients) with quantitative synthesis and bias assessment.
Limitations
- Heterogeneity in study designs (prospective and retrospective) and incomplete reporting of some outcomes (e.g., truncated HbA1c details in abstract).
- Non-randomized evidence base limits causal inference; residual confounding possible.
Future Directions: Prospective randomized comparisons versus first-generation somatostatin analogs with standardized metabolic endpoints; evaluate preventive glycemic strategies (e.g., SGLT2i/GLP-1RA) co-initiated with pasireotide.
BACKGROUND: Pasireotide long-acting release (PasiLAR), a somatostatin multireceptor ligand, is effective in achieving biochemical control but can increase the risk of hyperglycemia in acromegaly. However, the impact of PasiLAR on lipid and glucose metabolism in patients with acromegaly has not been systematically studied. This systematic review aimed at synthesizing evidence on PasiLAR effects (as monotherapy or combination therapy with pegvisomant) on lipid and glucose metabolism in patients with acromegaly. METHODS: MEDLINE, Embase, Cochrane Library, and Web of Science were searched for studies published between 2000 and 2024. Prospective and retrospective studies reporting metabolic outcomes before and under PasiLAR treatment for a minimum follow-up of 6 months. Two reviewers screened eligible publications (3441), extracted outcomes, and assessed risk of bias. RESULTS: Nineteen studies (896 patients) were included in the meta-analysis. PasiLAR was associated with increased fasting plasma glucose (FPG) (mean difference [MD] 23.4 mg/dL, 95% confidence interval [95%CI] 18.8-28.1]) and glycated hemoglobin (HbA CONCLUSIONS: In this large meta-analysis, PasiLAR was associated with increased HDL-C, FPG, HbA1c, and frequency of DM in patients with acromegaly. There was no effect on triglycerides, total cholesterol, and LDL-C. PROSPERO REGISTRATION NUMBER: CRD42024544686.